EP1849470B1 - Arzneistoff gegen krebs mit alpha, alpha, alpha-trifluorthymidin und thymidin-phosphorylase-inhibitor - Google Patents

Arzneistoff gegen krebs mit alpha, alpha, alpha-trifluorthymidin und thymidin-phosphorylase-inhibitor Download PDF

Info

Publication number
EP1849470B1
EP1849470B1 EP06712292.9A EP06712292A EP1849470B1 EP 1849470 B1 EP1849470 B1 EP 1849470B1 EP 06712292 A EP06712292 A EP 06712292A EP 1849470 B1 EP1849470 B1 EP 1849470B1
Authority
EP
European Patent Office
Prior art keywords
cancer
dose
drug
day
ftd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06712292.9A
Other languages
English (en)
French (fr)
Other versions
EP1849470B2 (de
EP1849470A1 (de
EP1849470A4 (de
Inventor
Tomohiro Emura
Akira Mita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1849470(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Priority to PL06712292T priority Critical patent/PL1849470T3/pl
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to SI200632192T priority patent/SI1849470T1/sl
Publication of EP1849470A1 publication Critical patent/EP1849470A1/de
Publication of EP1849470A4 publication Critical patent/EP1849470A4/de
Publication of EP1849470B1 publication Critical patent/EP1849470B1/de
Application granted granted Critical
Priority to HUS1700032C priority patent/HUS1700032I1/hu
Publication of EP1849470B2 publication Critical patent/EP1849470B2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a drug for the treatment of cancer (hereinafter may be referred to as "a cancer therapeutic drug”) which is an anticancer agent containing ⁇ , ⁇ , ⁇ -trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI) in combination, and exhibits enhanced cancer therapeutic effect.
  • a cancer therapeutic drug an anticancer agent containing ⁇ , ⁇ , ⁇ -trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI) in combination, and exhibits enhanced cancer therapeutic effect.
  • ⁇ , ⁇ , ⁇ -Trifluorothymidine is a nucleoside analogue with substitution of a methyl group to trifluoromethyl group at the 5-position of thymidine, and was previously synthesized by Heidelberger, et al. (Non-Patent Documents 1 and 2).
  • FTD fluorouracil
  • FU fluorouracil
  • F 3 TMP trifluorothymidine monophosphate
  • F 3 TMP binds to thymidylate synthase (TS), thereby exhibiting DNA synthesis inhibitory effect
  • FU-based antitumor agent has been a drug of choice in clinical practice, and its main mechanism of action is considered TS inhibition; however, recent studies have revealed that some patients are less sensitive to the FU-based antitumor agent (Non-Patent Documents 5 to 7).
  • FTD which is incorporated into DNA, has been considered to exhibit an antitumor effect different from that of an FU-based antitumor agent, and thus to become a clinically useful antitumor agent overcoming the aforementioned problem.
  • Non-Patent Document 8 intravenously administered FTD is degraded by thymidine phosphorylase (TP) in vivo, resulting in a very short half-life of FTD in the blood (i.e., about 12 minutes)
  • TP thymidine phosphorylase
  • this administration means poses problems in that, for example, the means lacks flexibility in use and causes hematological toxicity and gastrointestinal toxicity, and the means does not necessarily contribute to survival period even in some patients showing tumor shrinkage (Non-Patent Document 9).
  • an object of the present invention is to provide a cancer therapeutic drug exhibiting higher efficacy.
  • the present inventors have changed the dosage schedule of the above-described combination drug so that the drug is orally administered to a human twice daily.
  • administration of the drug at a low daily dose of 20 to 80 mg/m 2 exhibits remarkable anticancer effect, although it is that once-a-day administration of the drug requires a daily dose of 100 mg/m 2 (as a dose of FTD).
  • the present invention has been accomplished on the basis of this finding.
  • the present invention provides a cancer therapeutic drug, which is a composition containing alpha, alpha, alpha-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride (hereinafter may be referred to as "TPI-1”) in a molar ratio of 1 : 0.5 (hereinafter the composition may be referred to as "TAS-102”) for use in the treatment of cancer in a human patient in need thereof by orally administering the drug at a dose, as dose of FTD, of 20 to 80 mg/m 2 /day twice daily.
  • FTD alpha, alpha, alpha-trifluorothymidine
  • TIS-102 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride
  • the present disclosure also relates to the use of a composition containing ⁇ , ⁇ , ⁇ -trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1 : 0.5 for producing a cancer therapeutic drug which is orally administered to a patient in need thereof at a dose, as dose of FTD, of 20 to 80 mg/m 2 /day twice daily to four times daily.
  • FTD ⁇ , ⁇ , ⁇ -trifluorothymidine
  • 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1 : 0.5 for producing a cancer therapeutic drug which is orally administered to a patient in need thereof at a dose, as dose of FTD, of 20 to 80 mg/m 2 /day twice daily to four times daily.
  • the present disclosure also relates to a method for treatment of cancer, characterized in that the method comprises orally administering a composition containing ⁇ , ⁇ , ⁇ -trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1 : 0.5 to a patient in need thereof at a dose, as dose of FTD, of 20 to 80 mg/m 2 /day twice daily to four times daily.
  • FTD ⁇ , ⁇ , ⁇ -trifluorothymidine
  • 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1 : 0.5 to a patient in need thereof at a dose, as dose of FTD, of 20 to 80 mg/m 2 /day twice daily to four times daily.
  • the composition used in the present invention contains FTD and TPI-1 in a molar ration of 1 : 0.5.
  • FTD i.e., ⁇ , ⁇ , ⁇ -trifluorothymidine
  • TPI-1 is a drug which prevents inactivation of FTD due to degradation by inhibiting thymidine phosphorylase, which is a degradative enzyme for FTD.
  • the composition may be in the form of a single preparation containing both FTD and TPI-1, or combination of an FTD-containing preparation and a TPI-1-containing preparation.
  • Examples of the form of such a preparation include tablets, coated tablets, pills, powders, granules, capsules, solutions, suspensions, and emulsions or the like.
  • Such preparations may be formulated by use of, for example, a pharmaceutically acceptable carrier and the like through a conventional formulation method which is generally known in the art.
  • Such a preparation may be appropriately divided and packaged so that a dose of 20 to 80 mg/m 2 /day is administered twice daily.
  • No particular limitation is imposed on the method for packaging a preparation, so long as the method is an established method generally known in the art.
  • a tablet may be packaged in a material used for moisture- and oxygen-impervious packaging.
  • Examples of carriers which may be used for forming tablets include excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, and silicic acid; binders such as water, ethanol, propanol, cornstarch, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, potassium phosphate, and polyvinylpyrrolidone; disintegrators such as dry starch, sodium alginate, agar powder, laminaran powder, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, monoglyceride stearate, starch, and lactose; disintegration inhibitors such as sucrose, stearic acid, cacao butter, and hydrogenated oil; absorption promoters such as quaternary ammonium bases and sodium lau
  • Examples of carriers which may be used for forming a pills include excipients such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, kaolin, and talc; binders such as powdered acacia, powdered tragacanth, gelatin, and ethanol; and disintegrators such as laminaran and agar.
  • excipients such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, kaolin, and talc
  • binders such as powdered acacia, powdered tragacanth, gelatin, and ethanol
  • disintegrators such as laminaran and agar.
  • a capsule is prepared through an ordinary method by mixing the aforementioned active ingredients with any of the above-exemplified carriers, and by filling the resultant mixture into, for example, a hard gelatin capsule or a soft capsule.
  • An oral liquid preparation (e.g., an oral solution, a syrup, or an elixir) may be prepared through an ordinary method by use of, for example, a flavoring agent, a buffer, a stabilizer, or a smell correcting agent.
  • a flavoring agent include sucrose, bitter orange peel, citric acid, and tartaric acid
  • examples of the buffer include sodium citrate
  • examples of the stabilizer include tragacanth, gum arabic, and gelatin.
  • each of the aforementioned preparations may contain an additional additive such as a coloring agent, a preservative, a perfume, a seasoning agent, or a sweetener, or an additional pharmaceutical drug.
  • an additional additive such as a coloring agent, a preservative, a perfume, a seasoning agent, or a sweetener, or an additional pharmaceutical drug.
  • the composition of the present invention is orally administered at a dose of 20 to 80 mg/m 2 /day (as a dose of FTD) twice daily.
  • the daily dose is more preferably 25 to 75 mg/m 2 /day, much more preferably 30 to 75 mg/m 2 /day, particularly preferably 50 to 70 mg/m 2 /day, as a dose of FTD.
  • Dose of the composition administered to a patient in need thereof is determined on the basis of the body surface area (BSA) of the patient calculated from the patient's height and body weight.
  • BSA body surface area
  • Body surface area of a patient is calculated through a conventional method which is appropriately selected in consideration of, for example, the race, sex, health condition, and symptom of the patient.
  • Body surface area is calculated by use of, for example, any of the following calculation formulas 1 to 5, preferably the formula 1 or 2(a).
  • the composition is orally administered at a dose of 20 to 80 mg/m 2 /day (as a dose of FTD) twice daily.
  • the composition is administered at intervals of six hours or more.
  • a weekly dosage schedule may consist of daily administration, but preferably, the schedule consists of five-day administration and two-day rest, from the viewpoint of reduction of burden on patients. More preferably, a weekly dosage cycle consisting of five-day administration and two-day rest is carried out for two weeks, followed by rest for two weeks.
  • cancers to which the cancer therapeutic drug of the present invention is applied include, but are not particularly limited to, esophageal cancer, gastric cancer, liver cancer, gallbladder/bile duct cancer, pancreatic cancer, colorectal cancer, head and neck cancer, lung cancer, breast cancer, cervical cancer, ovarian cancer, bladder cancer, prostate cancer, testicular tumor, soft tissue and bone sarcoma, skin cancer, malignant lymphoma, leukemia, and brain tumor.
  • malignant solid cancers such as gastric cancer, pancreatic cancer, breast cancer, colorectal cancer, head and neck cancer, gallbladder/bile duct cancer, and lung cancer.
  • the present invention even when the therapeutic drug is administered at a dose lower than that in the case of conventional once-a-day administration, very excellent cancer therapeutic effect is obtained. This is because, the amount of FTD incorporated into target site DNA is increased through administration twice daily.
  • the method of the present invention facilitates control of side effects.
  • Formulation Example 1 FTD 20.00 mg TPI-1 9.42 mg Lactose 70.00 mg Crystalline cellulose 3.50 mg Magnesium stearate 1.00 mg Talc 1.00 mg Cornstarch 3.50 mg Hydroxypropylmethylcellulose 25.00 mg Total weight (per tablet) 133.42 mg
  • Granules were prepared from the aforementioned formulation ratio according to an ordinary method.
  • Formulation Example 4 FTD 10.00 mg TPI-1 4.71 mg Lactose 24.00 mg Crystalline cellulose 12.50 mg Magnesium stearate 1.00 mg Total weight (per capsule) 52.21 mg
  • Capsules were prepared from the aforementioned formulation ratio according to an ordinary method.
  • TAS-102 Therapeutic effect of TAS-102 was studied by orally administering TAS-102 to cancer patients at a dose of 100 mg/m 2 (as a dose of FTD) once a day (trial 1), or at a dose of 70 mg/m 2 (as a dose of FTD) thrice a day (trial 2).
  • TAS-102 trials were performed in patients with gastrointestinal cancer for which standard therapy is ineffective or no curative therapy exists, for the main purpose of evaluating safety of TAS-102.
  • the trials correspond to a phase I clinical trial for determining the recommended dose (RD) of TAS-102 at which the drug can be safely administered without causing problematic side effects in phase II clinical trials carried out in each of different cancer types. If possible, therapeutic effect of the drug on tumor is evaluated through the trials.
  • RD recommended dose
  • the tumor-shrinking effect of the drug was determined on the basis of comprehensive evaluation of target lesions (i.e., lesions having a size equal to or greater than a measurable size corresponding to slice thickness in CT or a similar technique) and non-target lesions (i.e., all lesions other than the target lesions) with reference to the RECIST evaluation method ( Journal of the National Cancer Institute, 2000, Vol. 92, No. 3, 205-216 ).
  • target lesions i.e., lesions having a size equal to or greater than a measurable size corresponding to slice thickness in CT or a similar technique
  • non-target lesions i.e., all lesions other than the target lesions
  • PR partial response
  • PD progressive disease
  • SD stable disease
  • PD tumor progression is not enough to be regarded as “PD”; i.e., progression of tumor is stopped, and no exacerbation of tumor is observed.
  • MR minimal response
  • MR tumor-shrinking effect is lower as compared with that of "PR” (i.e., reduction in the sum of the lesion major axis lengths is less than 30%), but is maintained at a comparable level (i.e., reduction in the sum of the lesion major axis lengths is about 15%), or the case where therapeutic effect corresponding to "PR" is observed temporarily.
  • Fig. 1 corresponds to administration of a TAS-102 preparation (tablets) at a dose of 100 mg/m 2 (as a dose of FTD) once a day (five-day administration and two-day rest per week). The data show that the drug administration was effective (i.e., stable disease without exacerbation of tumor) for two of six patients (33%).
  • “Trial 2” corresponds to administration of a TAS-102 preparation (tablets) at a dose of 70 mg/m 2 (as a dose of FTD) thrice daily (five-day administration and two-day rest per week). The data show that the drug administration was effective for four of six patients (67%).
  • TAS-102 in a divided manner is an effective administration method for patients with gastrointestinal cancer for which standard therapy is ineffective or no curative therapy exists.
  • phase I clinical trials were performed in breast cancer patients.
  • TAS-102 Therapeutic effect of TAS-102 was studied by orally administering TAS-102 to patients with breast cancer for which standard therapy is ineffective or no curative therapy exists at a dose of 60 mg/m 2 /day (as a dose of FTD) twice a day (trial 3), or at a dose of 50 mg/m 2 /day (as a dose of FTD) twice a day (trial 4).
  • Fig. 2 The results are shown in Fig. 2 .
  • "Trial 3" corresponds to administration of a TAS-102 preparation (tablets) at a dose of 60 mg/m 2 (as a dose of FTD) twice daily (five-day administration and two-day rest per week). The data show that the drug administration was effective for five of seven patients (71%).
  • "Trial 4" corresponds to administration of a TAS-102 preparation (tablets) at a dose of 50 mg/m 2 (as a dose of FTD) twice daily (five-day administration and two-day rest per week). The data show that the drug administration was effective for seven of nine patients (78%). Specifically, in most patients, progression of tumor was stopped, and no exacerbation of tumor was observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (9)

  1. Therapeutisches Krebsmedikament, welches eine Zusammensetzung ist, die α,α,α-Trifluorthymidin (TFD) und 5-Chlor-6-(1-(2-iminopyrrolidinyl)methyl)uracil-hydrochlorid in einem molaren Verhältnis von 1:0,5 umfasst, zur Verwendung bei der Behandlung von Krebs in einem menschlichen Patienten, der dessen bedarf, durch orale Verabreichung des Medikaments in einer Dosis, als Dosis von FTD, von 20 bis 80 mg/m2/Tag, zweimal täglich.
  2. Therapeutisches Krebsmedikament zur Verwendung nach Anspruch 1, wobei das Medikament einem Patienten, der dessen bedarf, in einer Dosis, als Dosis von FTD, von 25 bis 75 mg/m2/Tag, zweimal täglich verabreicht wird.
  3. Therapeutisches Krebsmedikament zur Verwendung nach Anspruch 1, wobei das Medikament zweimal täglich nach einem auf einer Woche basierenden Plan, der eine Verabreichung für 5 Tage und eine zweitägige Pause einschließt, verabreicht wird.
  4. Therapeutisches Krebsmedikament zur Verwendung nach Anspruch 1, wobei das Medikament auf eine solche Weise verabreicht wird, dass ein wöchentlicher Dosiszyklus, der aus einer Verabreichung für 5 Tage und einer zweitägigen Pause besteht, für zwei Wochen durchgeführt wird, gefolgt von einer zweiwöchigen Pause.
  5. Therapeutisches Krebsmedikament zur Verwendung nach Anspruch 1, wobei das Medikament einem Patienten, der dessen bedarf, mit einer Dosis, als Dosis von FTD, von 50 bis 70 mg/m2/Tag verabreicht wird.
  6. Therapeutisches Krebsmedikament zur Verwendung nach einem der Ansprüche 1 bis 5, wobei das Medikament einem Patienten, der dessen bedarf, in einer Dosis, als Dosis von FTD, von 70 mg/m2/Tag verabreicht wird.
  7. Therapeutisches Krebsmedikament zur Verwendung nach einem der Ansprüche 1 bis 6, wobei der Krebs, an dem das therapeutische Krebsmedikament angewendet wird, Speiseröhrenkrebs, Magenkrebs, Leberkrebs, Gallenblasen-/Gallengangkrebs, Bauchspeicheldrüsenkrebs, Dickdarmkrebs, Kopf-Hals-Karzinom, Lungenkrebs, Brustkrebs, Gebärmutterhalskrebs, Ovarialkarzinom, Blasenkrebs, Prostatakrebs, Hodenkrebs, Weichteil- und Knochensarkome, Hautkrebs, malignes Lymphom, Leukämie und Hirntumor einschließt.
  8. Therapeutisches Krebsmedikament zur Verwendung nach einem der Ansprüche 1 bis 7, wobei der Krebs, an dem das therapeutische Krebsmedikament angewendet wird, maligne solide Tumore einschließt, ausgewählt aus Magenkrebs, Bauchspeicheldrüsenkrebs, Brustkrebs, Dickdarmkrebs, Kopf-Hals-Karzinom, Gallenblasen-/Gallengangkrebs und Lungenkrebs.
  9. Therapeutisches Krebsmedikament zur Verwendung nach einem der Ansprüche 1 bis 8, wobei die Dosis der Zusammensetzung, die an den Patienten, der dessen bedarf, verabreicht wird, auf Basis der Körperoberfläche des Patienten bestimmt wird, wobei die Körperoberfläche durch Verwenden einer beliebigen der folgenden Berechnungsformeln 1 bis 5 berechnet wird:
    1. Die Mosteller-Formel (siehe N. Engl. J. Med. 1987 Oct 22; 317 (17): 1098 (Letter)) K o ¨ rperoberfl a ¨ che m 2 = Gr o ¨ ße cm × Gewicht kg / 3600 1 / 2
    Figure imgb0012
    2. Die DuBois- und DuBois-Formel (siehe Arch. Int. Med. 1916 17: 863-71; J. Clin. Anesth. 1992; 4 (1): 4-10)
    (a) Körperoberfläche (m2) = 0,20247 x Größe (m)0,725 x Gewicht (kg)0,425
    (b) Körperoberfläche (m2) = 0,007184 x Größe (cm)0,725 x Gewicht (kg)0,425
    3. Die Haycock-Formel (siehe The Journal of Pediatrics 1978 93: 1: 62-66) K o ¨ rperoberfl a ¨ che m 2 = 0 , 024265 × Gr o ¨ ße cm 0 , 3964 × Gewicht kg 0 , 5378
    Figure imgb0013
    4. Die Gehan and George-Formel (siehe Cancer Chemother. Rep. 1970 54: 225-35) K o ¨ rperoberfl a ¨ che m 2 = 0 , 0235 × Gr o ¨ ße cm 0.42246 × Gewicth kg 0.51456
    Figure imgb0014
    5. Die Boyd-Formel (siehe Minneapolis: University of Minnesota Press, 1935) K o ¨ rperoberfl a ¨ che m 2 = 0 , 0003207 × Gr o ¨ ße cm 0 , 3 × Gewicht Gramm 0 , 7285 − ( 0 , 0188 × LOG Gramm
    Figure imgb0015
EP06712292.9A 2005-01-26 2006-01-25 Arzneistoff gegen krebs mit alpha, alpha, alpha-trifluorthymidin und thymidin-phosphorylase-inhibitor Active EP1849470B2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI200632192T SI1849470T1 (sl) 2005-01-26 2006-01-25 Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze
PL06712292T PL1849470T3 (pl) 2005-01-26 2006-01-25 Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej
HUS1700032C HUS1700032I1 (hu) 2005-01-26 2017-08-01 Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (4)

Publication Number Publication Date
EP1849470A1 EP1849470A1 (de) 2007-10-31
EP1849470A4 EP1849470A4 (de) 2010-12-08
EP1849470B1 true EP1849470B1 (de) 2017-06-21
EP1849470B2 EP1849470B2 (de) 2024-03-20

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06712292.9A Active EP1849470B2 (de) 2005-01-26 2006-01-25 Arzneistoff gegen krebs mit alpha, alpha, alpha-trifluorthymidin und thymidin-phosphorylase-inhibitor

Country Status (19)

Country Link
EP (1) EP1849470B2 (de)
JP (1) JP5576591B2 (de)
KR (1) KR101468216B1 (de)
AU (1) AU2006209547C1 (de)
CA (1) CA2594713A1 (de)
CY (2) CY1119393T1 (de)
DK (1) DK1849470T4 (de)
ES (1) ES2630002T3 (de)
FI (1) FI1849470T4 (de)
HU (2) HUE033306T2 (de)
LT (2) LT1849470T (de)
LU (1) LUC00036I2 (de)
NL (1) NL300889I2 (de)
PL (1) PL1849470T3 (de)
PT (1) PT1849470T (de)
RU (1) RU2394581C2 (de)
SI (1) SI1849470T1 (de)
TW (1) TWI362265B (de)
WO (1) WO2006080327A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3042669B1 (de) 2013-09-06 2023-03-08 Taiho Pharmaceutical Co., Ltd. Antitumormittel und antitumorwirkungsverstärker

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
HUE033306T2 (hu) 2005-01-26 2017-11-28 Taiho Pharmaceutical Co Ltd Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) * 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
RU2508092C2 (ru) 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
WO2009138507A2 (en) * 2008-05-15 2009-11-19 Katholieke Universiteit Leuven, K.U. Leuven R&D Anti-cancer combination therapy
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
RU2607499C2 (ru) 2010-09-02 2017-01-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
JP5832541B2 (ja) * 2011-08-16 2015-12-16 大鵬薬品工業株式会社 Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
EP2819656A1 (de) 2012-02-28 2015-01-07 Grünenthal GmbH Fälschungssichere dosierform mit einer pharmazeutisch aktiven verbindung und einem anionischen polymer
US9340808B2 (en) 2012-03-14 2016-05-17 Nisshin Pharma Inc. Sulfur amino acid-containing composition
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX360892B (es) 2012-05-16 2018-11-20 Novartis Ag Régimen de dosificación para un inhibidor de cinasa pi-3.
KR101847252B1 (ko) * 2013-03-27 2018-04-09 다이호야쿠힌고교 가부시키가이샤 이리노테칸염산염 수화물을 함유하는 항종양제
RU2668125C2 (ru) * 2013-03-27 2018-09-26 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
KR101928618B1 (ko) 2013-05-17 2018-12-12 다이호야쿠힌고교 가부시키가이샤 Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법
EP3003283A1 (de) 2013-05-29 2016-04-13 Grünenthal GmbH Manipulationssichere darreichungsform mit bimodalem freisetzungsprofil
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
EP3142646A1 (de) 2014-05-12 2017-03-22 Grünenthal GmbH Manipulationssichere kapselformulierung mit tapentadol mit unmittelbarer freisetzung
EP3148512A1 (de) 2014-05-26 2017-04-05 Grünenthal GmbH Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
MA43590A (fr) * 2016-01-08 2018-11-14 Taiho Pharmaceutical Co Ltd Agent antitumoral contenant un immunomodulateur et un amplificateur d'effet antitumoral
WO2017135412A1 (ja) * 2016-02-05 2017-08-10 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
EP3730935A4 (de) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. Verfahren zur detektion von analoga aus trifluridin und/oder tipiracil
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0763529A1 (de) 1995-03-29 1997-03-19 Taiho Pharmaceutical Company Limited Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
WO2006080327A1 (ja) 2005-01-26 2006-08-03 Taiho Pharmaceutical Co., Ltd. α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255314B1 (en) * 1996-09-24 2001-07-03 Taiho Charmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0763529A1 (de) 1995-03-29 1997-03-19 Taiho Pharmaceutical Company Limited Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
WO2006080327A1 (ja) 2005-01-26 2006-08-03 Taiho Pharmaceutical Co., Ltd. α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", GUIDANCE FOR INDUSTRY, July 2005 (2005-07-01)
GREEN ET AL.: "Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)", JOURNAL OF CLINICAL ONCOLOGY, June 2006 (2006-06-01), XP055480004

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3042669B1 (de) 2013-09-06 2023-03-08 Taiho Pharmaceutical Co., Ltd. Antitumormittel und antitumorwirkungsverstärker

Also Published As

Publication number Publication date
AU2006209547A1 (en) 2006-08-03
AU2006209547B2 (en) 2011-05-26
LTC1849470I2 (lt) 2019-10-25
LT1849470T (lt) 2017-07-25
EP1849470B2 (de) 2024-03-20
CY1119393T1 (el) 2018-02-14
NL300889I1 (nl) 2017-08-14
KR101468216B1 (ko) 2014-12-03
EP1849470A1 (de) 2007-10-31
DK1849470T4 (en) 2024-04-02
DK1849470T3 (en) 2017-08-14
ES2630002T3 (es) 2017-08-17
WO2006080327A1 (ja) 2006-08-03
JP5576591B2 (ja) 2014-08-20
HUE033306T2 (hu) 2017-11-28
CA2594713A1 (en) 2006-08-03
NL300889I2 (nl) 2018-01-16
EP1849470A4 (de) 2010-12-08
HUS1700032I1 (hu) 2017-09-28
CY2017029I1 (el) 2018-02-14
FI1849470T4 (fi) 2024-03-22
LTPA2017024I1 (lt) 2017-08-10
LUC00036I1 (de) 2017-10-02
KR20070104559A (ko) 2007-10-26
CY2017029I2 (el) 2018-02-14
RU2394581C2 (ru) 2010-07-20
SI1849470T1 (sl) 2017-10-30
PL1849470T3 (pl) 2017-11-30
JPWO2006080327A1 (ja) 2008-06-19
LUC00036I2 (de) 2017-12-01
RU2007132181A (ru) 2009-03-10
TWI362265B (en) 2012-04-21
AU2006209547C1 (en) 2022-04-07
TW200637562A (en) 2006-11-01
PT1849470T (pt) 2017-09-22

Similar Documents

Publication Publication Date Title
EP1849470B1 (de) Arzneistoff gegen krebs mit alpha, alpha, alpha-trifluorthymidin und thymidin-phosphorylase-inhibitor
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
EP1864683A1 (de) Strahlentherapieverstärker
US7863255B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
JP5066737B2 (ja) シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
WO2009119092A1 (ja) シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤
JPWO2012105486A1 (ja) １日１回隔日投与を特徴とするテガフール含有組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20101109

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7068 20060101AFI20060808BHEP

Ipc: A61P 35/00 20060101ALI20101103BHEP

Ipc: A61K 31/7072 20060101ALI20101103BHEP

Ipc: A61K 31/513 20060101ALI20101103BHEP

Ipc: A61K 45/06 20060101ALI20101103BHEP

Ipc: A61K 31/506 20060101ALI20101103BHEP

17Q First examination report despatched

Effective date: 20111027

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602006052835

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031706800

Ipc: A61K0031707200

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/513 20060101ALI20161130BHEP

Ipc: A61P 35/00 20060101ALI20161130BHEP

Ipc: A61K 31/7072 20060101AFI20161130BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/513 20060101ALI20161205BHEP

Ipc: A61K 31/7072 20060101AFI20161205BHEP

Ipc: A61K 31/506 20060101ALI20161205BHEP

Ipc: A61P 35/00 20060101ALI20161205BHEP

Ipc: A61K 31/7068 20060101ALI20161205BHEP

INTG Intention to grant announced

Effective date: 20170103

RIN1 Information on inventor provided before grant (corrected)

Inventor name: EMURA, TOMOHIRO

Inventor name: MITA, AKIRA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TAIHO PHARMACEUTICAL CO., LTD.

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 902332

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170715

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006052835

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: TRIFLURIDINE/TIPIRACIL; REGISTRATION NO/DATE: EU/1/16/1096 20160425

Spc suppl protection certif: 17C1028

Filing date: 20170808

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: TRIFLURIDINE/TIPIRACIL; REGISTRATION NO/DATE: EU/1/16/1096 20160427

Spc suppl protection certif: 17C1028

Filing date: 20170808

REG Reference to a national code

Ref country code: LT

Ref legal event code: SPCF

Free format text: PRODUCT NAME: TRIFLURIDINAS/TIPIRACILAS; REGISTRATION NO/DATE: EU/1/16/1096 20160425

Spc suppl protection certif: PA2017024

Filing date: 20170728

Expiry date: 20260125

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20170811

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2630002

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170817

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCF

Free format text: PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACIL OF EEN ZOUT VAN TIPIRACIL, ZOALS TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427

Spc suppl protection certif: 300889

Filing date: 20170808

Expiry date: 20260124

Extension date: 20310124

REG Reference to a national code

Ref country code: IE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A SALT OF TIPIRACIL SUCH AS TIPIRACIL HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160425

Spc suppl protection certif: 2017/033

Filing date: 20170731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R065

Ref document number: 602006052835

Country of ref document: DE

Free format text: PRODUCT NAME: TRIFLURIDIN IN KOMBINATION MIT TIPIRACIL ODER EINEM SALZ VON TIPIRACIL WIE TIPIRACIL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1096 20160425

Spc suppl protection certif: 122017000052

Filing date: 20170803

Expiry date: 20260126

REG Reference to a national code

Ref country code: FI

Ref legal event code: SPCF

Spc suppl protection certif: C20170040

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFF

Free format text: PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427

Spc suppl protection certif: CA 2017 00036

Filing date: 20170822

Expiry date: 20260125

Extension date: 20310125

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCF

Ref document number: 502017000101059

Country of ref document: IT

Free format text: PRODUCT NAME: TRIFLURDINA IN COMBINAZIONE CON TIPIRACILE O UN SALE DI TIPIRACILE QUALE TIPIRACILE IDROCLORURO(LONSURF); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1096, 20160427

Spc suppl protection certif: 132017000102371

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFF

Free format text: PRODUCT NAME: TRIFLURIDINE WITH TIPACRIL OR A SALT OF TIPACRIL SUCH AS TIPACRIL HYDROCHLORIDE; REGISTERED: UK EU/1/16/1096 20160427

Spc suppl protection certif: SPC/GB17/049

Filing date: 20170816

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 1849470

Country of ref document: PT

Date of ref document: 20170922

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20170915

REG Reference to a national code

Ref country code: HU

Ref legal event code: AA1S

Ref document number: E033306

Country of ref document: HU

Spc suppl protection certif: S1700032

Filing date: 20170801

REG Reference to a national code

Ref country code: IT

Ref legal event code: SPCG

Ref document number: 502017000101059

Country of ref document: IT

Free format text: PRODUCT NAME: TRIFLURDINA IN COMBINAZIONE CON TIPIRACILE O UN SALE DI TIPIRACILE QUALE TIPIRACILE IDROCLORURO(LONSURF); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1096, 20160427

Spc suppl protection certif: 132017000102371

Extension date: 20310125

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCF

Ref document number: 902332

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: TRIFLURIDIN / TIPIRACIL ODER DEREN PHARMAZEUTISCH WIRKSAMEN SALZE; REGISTRATION NO/DATE: EU/1/16/1096 (MITTEILUNG) 20160427

Spc suppl protection certif: 34/2017

Filing date: 20170809

Effective date: 20171015

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCF

Free format text: PRODUCT NAME: TRIFLURIDIN ET TIPIRACIL; REGISTRATION NO/DATE: SWISSMEDIC 66219 25.08.2017

Filing date: 20171020

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E014243

Country of ref document: EE

Effective date: 20170901

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20170402408

Country of ref document: GR

Effective date: 20171122

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E033306

Country of ref document: HU

REG Reference to a national code

Ref country code: BE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: LONSURF - TRIFLURIDINE/TIPIRACIL; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20160427

Spc suppl protection certif: 2017C/028

Filing date: 20170803

Expiry date: 20260125

Extension date: 20310125

REG Reference to a national code

Ref country code: LU

Ref legal event code: SPCF

Free format text: PRODUCT NAME: TRIFLURIDINE COMBINEE AU TIPIRACIL OU UN SEL DE TIPIRACIL TEL QUE L'HYDROCHLORURE DE TIPIRACIL; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20160427

Spc suppl protection certif: LUC00036

Filing date: 20170929

Expiry date: 20260125

Extension date: 20310125

Ref country code: LU

Ref legal event code: SPCG

Free format text: PRODUCT NAME: TRIFLURIDINE COMBINEE AU TIPIRACIL OU UN SEL DE TIPIRACIL TEL QUE L'HYDROCHLORURE DE TIPIRACIL; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20160427

Spc suppl protection certif: LUC00036

Filing date: 20170929

Expiry date: 20260125

Extension date: 20310125

Effective date: 20171201

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCG

Ref document number: 902332

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: TRIFLURIDIN / TIPIRACIL ODER DEREN PHARMAZEUTISCH WIRKSAMEN SALZE; REGISTRATION NO/DATE: EU/1/16/1096 (MITTEILUNG) 20160427

Spc suppl protection certif: 34/2017

Filing date: 20170809

Expiry date: 20260125

Extension date: 20310125

Effective date: 20171215

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A SALT OF TIPIRACIL SUCH AS TIPIRACIL HYDROCHLORIDE; REG. NO/DATE: EU/1/16/1096 20160427

Spc suppl protection certif: 1790063-0

REG Reference to a national code

Ref country code: SK

Ref legal event code: SPCF

Free format text: PRODUCT NAME: TRIFLURIDIN/TIPIRACIL VO VSETKYCH FORMACH CHRA- NENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1096 20160427

Spc suppl protection certif: 20-2017

Filing date: 20171110

Ref country code: SK

Ref legal event code: T3

Ref document number: E 25223

Country of ref document: SK

REG Reference to a national code

Ref country code: EE

Ref legal event code: AA1Y

Ref document number: E014243

Country of ref document: EE

Free format text: PRODUCT NAME: TRIFLURIDIIN/TIPIRATSIIL;REG NO/DATE: EU/1/16/1096 27.04.2016

Spc suppl protection certif: C20170042

Filing date: 20171208

REG Reference to a national code

Ref country code: NL

Ref legal event code: SPCG

Free format text: PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427

Spc suppl protection certif: 300889

Filing date: 20170808

Expiry date: 20260124

Extension date: 20310124

Effective date: 20180116

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602006052835

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: STADA ARZNEIMITTEL AG

Effective date: 20180321

Opponent name: GENERICS (U.K.) LIMITED

Effective date: 20180321

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: FR

Ref legal event code: CT

Free format text: PRODUCT NAME: TRIFLURIDINE/TIPIRACIL; REGISTRATION NO/DATE: EU/1/16/1096 20160427

Spc suppl protection certif: 17C1028

Filing date: 20170808

Extension date: 20310124

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCG

Free format text: PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REG. NO/DATE: EU/1/16/1096 20160427

Spc suppl protection certif: 1790063-0

Expiry date: 20260126

Extension date: 20310125

REG Reference to a national code

Ref country code: FR

Ref legal event code: AV

Effective date: 20181106

REG Reference to a national code

Ref country code: IE

Ref legal event code: SPCG

Free format text: PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160425

Spc suppl protection certif: 2017/033

Extension date: 20310124

Effective date: 20190123

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 902332

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170621

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APAW Appeal reference deleted

Free format text: ORIGINAL CODE: EPIDOSDREFNO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

REG Reference to a national code

Ref country code: LT

Ref legal event code: SPCG

Free format text: PRODUCT NAME: TRIFLURIDINAS/TIPIRACILAS; REGISTRATION NO/DATE: EU/1/16/1096 20160425

Spc suppl protection certif: PA2017024,C1849470

Filing date: 20170728

Expiry date: 20260125

Extension date: 20310125

REG Reference to a national code

Ref country code: SK

Ref legal event code: SPCG

Free format text: PRODUCT NAME: TRIFLURIDIN/TIPIRACIL VO VSETKYCH FORMACH CHRA- NENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1096 20160427

Spc suppl protection certif: 322 20-2017

Filing date: 20171110

Extension date: 20310126

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: HU

Ref legal event code: FG4S

Ref document number: E033306

Country of ref document: HU

Spc suppl protection certif: S1700032

Filing date: 20170801

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFG

Free format text: PRODUCT NAME: TRIFLURIDINE WITH TIPACRIL HYDROCHLORIDE; REGISTERED: UK EU/1/16/1096/001(NI) 20160427; UK EU/1/16/1096/002(NI) 20160427; UK EU/1/16/1096/003(NI) 20160427; UK EU/1/16/1096/004(NI) 20160427; UK EU/1/16/1096/005(NI) 20160427; UK EU/1/16/1096/006(NI) 20160427; UK PLGB 05815/0112 20160427; UK PLGB 05815/0113 20160427

Spc suppl protection certif: SPC/GB17/049

Filing date: 20170816

Extension date: 20310124

Effective date: 20220211

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

REG Reference to a national code

Ref country code: RO

Ref legal event code: SPCG

Free format text: PRODUCT NAME: TRIFLURIDINA IN COMBINATIE CU TIPIRACIL SAU O SARE ACCEPTABILA FARMACEUTIC DE TIPIRACIL CUM AR FI CLORHIDRAT DE TIPIRACIL; NATIONAL AUTHORISATION NUMBER: EU/1/16/1096; DATE OF NATIONAL AUTHORISATION: 20160425; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1096; DATE OF FIRST AUTHORISATION IN EEA: 20160425

Spc suppl protection certif: C 2017 032

Extension date: 20310125

Effective date: 20220930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20230111

Year of fee payment: 18

REG Reference to a national code

Ref country code: EE

Ref legal event code: HC1A

Ref document number: E014243

Country of ref document: EE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230124

Year of fee payment: 18

Ref country code: IT

Payment date: 20221213

Year of fee payment: 18

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20231213

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231213

Year of fee payment: 19

Ref country code: GB

Payment date: 20231207

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20231228

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20231218

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231213

Year of fee payment: 19

Ref country code: RO

Payment date: 20231212

Year of fee payment: 19

Ref country code: NL

Payment date: 20231215

Year of fee payment: 19

Ref country code: LV

Payment date: 20231205

Year of fee payment: 19

Ref country code: LT

Payment date: 20231222

Year of fee payment: 19

Ref country code: IE

Payment date: 20231211

Year of fee payment: 19

Ref country code: FR

Payment date: 20231212

Year of fee payment: 19

Ref country code: FI

Payment date: 20231218

Year of fee payment: 19

Ref country code: EE

Payment date: 20231219

Year of fee payment: 19

Ref country code: BG

Payment date: 20231204

Year of fee payment: 19

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231228

Year of fee payment: 19

Ref country code: BE

Payment date: 20231219

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240112

Year of fee payment: 19

27A Patent maintained in amended form

Effective date: 20240320

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602006052835

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20240325

Ref country code: SE

Ref legal event code: RPEO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240202

Year of fee payment: 19

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20231227

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20231213

Year of fee payment: 19

Ref country code: DE

Payment date: 20231128

Year of fee payment: 19

Ref country code: CZ

Payment date: 20240117

Year of fee payment: 19

Ref country code: CY

Payment date: 20231212

Year of fee payment: 19

Ref country code: CH

Payment date: 20240202

Year of fee payment: 19

Ref country code: PT

Payment date: 20240124

Year of fee payment: 19

REG Reference to a national code

Ref country code: CH

Ref legal event code: SPCG

Free format text: PRODUCT NAME: TRIFLURIDIN ET TIPIRACIL; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 66219 25.08.2017

Spc suppl protection certif: C01849470/01

Filing date: 20171020

Extension date: 20310124

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20231221

Year of fee payment: 19

REG Reference to a national code

Ref country code: SK

Ref legal event code: T5

Ref document number: E 25223

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R067

Ref document number: 602006052835

Country of ref document: DE

Free format text: PRODUCT NAME: TRIFLURIDIN IN KOMBINATION MIT TIPIRACIL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1096 20160425

Spc suppl protection certif: 122017000052

Filing date: 20170803

Expiry date: 20260126

Extension date: 20310125

REG Reference to a national code

Ref country code: EE

Ref legal event code: LD4A

Ref document number: E014243

Country of ref document: EE